| Aug 8 |
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
|
| Jul 8 |
Bio-Path Holdings Provides Clinical Update and Expansion Plans
|
| Jun 12 |
Bio-Path files to sell 5.56M common stock, warrants
|
| Jun 5 |
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
|
| Jun 4 |
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
|
| Jun 3 |
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
|
